Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash & Current Investments (2021 - 2025)

LifeStance Health (LFST) has disclosed Cash & Current Investments for 5 consecutive years, with $248.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 103.54% to $248.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $248.6 million, a 103.54% increase, with the full-year FY2025 number at $248.6 million, up 103.54% from a year prior.
  • Cash & Current Investments was $248.6 million for Q4 2025 at LifeStance Health, up from $141.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $276.2 million in Q2 2021 to a low of $3.6 million in Q2 2024.
  • A 5-year average of $117.4 million and a median of $102.6 million in 2024 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: crashed 97.48% in 2024, then surged 5185.1% in 2025.
  • LifeStance Health's Cash & Current Investments stood at $148.0 million in 2021, then crashed by 94.02% to $8.9 million in 2022, then surged by 823.58% to $81.8 million in 2023, then soared by 49.42% to $122.2 million in 2024, then skyrocketed by 103.54% to $248.6 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Cash & Current Investments are $248.6 million (Q4 2025), $141.8 million (Q3 2025), and $189.4 million (Q2 2025).